MedTrace Logo

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NCT05386888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-10-02

No results posted yet for this study

Summary

This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).

Conditions

  • NSCLC, Stage III

Interventions

DRUG

GFH018

Administered as oral

DRUG

Toripalimab

Administered as an IV infusion

DRUG

Paclitaxel

Administered as an IV infusion

DRUG

Carboplatin

Administered as an IV infusion

DRUG

Cisplatin

Administered as an IV infusion

DRUG

Pemetrexed

Administered as an IV infusion

RADIATION

Thoracic Radiation Therapy (TRT)

Thoracic Radiation Therapy (TRT)

DRUG

GFH018

Administered as an IV infusion

Sponsors & Collaborators

  • Genfleet Therapeutics (Shanghai) Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05386888 on ClinicalTrials.gov